ICCM Stock Risk & Deep Value Analysis

Icecure Medical Ltd

DVR Score

6.9

out of 10

Solid Pick

What You Need to Know About ICCM Stock

We analyzed Icecure Medical Ltd using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran ICCM through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.

Updated Apr 12, 2026•Run Fresh Analysis →

ICCM Risk Analysis & Red Flags

What Could Go Wrong

The company is burning significant cash ($15.057M net loss in FY25) and recently underwent substantial dilution (up to 31.7% increase in shares outstanding) to raise $4.0M. If commercial adoption of ProSense does not accelerate rapidly enough to outpace cash burn, further significant dilution will be required, severely eroding shareholder value and making the path to profitability elusive.

Risk Matrix

Overall

Aggressive

Financial

High

Market

Medium

Competitive

Medium

Execution

Medium

Regulatory

Low

Red Flags

⚠
Declining gross margin from 44% (2024) to 36% (2025), indicating potential pricing pressure or cost issues.
⚠
Significant and recent share dilution (up to 31.7% increase in shares outstanding from offering and warrants).
⚠
Consistent EPS misses and substantial net losses ($15.057M in FY25) with no clear path to profitability.
⚠
High P/S (19.3x) and P/B (9.2x) ratios compared to sector medians (2.9-3.2x and 2.0-2.6x respectively) for a company with declining margins and heavy cash burn.
⚠
Lack of specified YoY revenue growth rate for full-year 2025, contrary to previous high growth narratives.

Upcoming Risk Events

📅
Slower-than-expected adoption of ProSense due to competition or physician reluctance
📅
Further dilutive capital raises needed to fund operations
📅
Negative results or delays from the ChoICE study

When to Reconsider

🚪
Exit if gross margin falls below 30% for two consecutive quarters.
🚪
Sell if quarterly revenue growth decelerates or remains flat below 50% YoY for two consecutive quarters.
🚪
Exit if another highly dilutive capital raise (e.g., >20% additional shares) is announced without substantial market expansion or accelerated revenue growth.

Unlock ICCM Risk Analysis & Red Flags

Create a free account to see the full analysis

Investment Thesis

Icecure Medical offers a compelling high-risk, high-reward investment opportunity driven by its innovative ProSense cryoablation system. With strong clinical validation (ICE3 trial data for breast cancer), recent FDA clearance, and inclusion in ASBrS guidelines, the company is poised to capture significant share in a large, untapped market for non-surgical tumor ablation. While current financial metrics like declining margins and significant dilution pose risks, the expanding clinical adoption and strong analyst conviction suggest substantial long-term growth potential if operational execution improves.

Is ICCM Stock Undervalued?

Icecure Medical shows strong promise with its ProSense cryoablation system, backed by FDA clearance for breast cancer and positive clinical data (ICE3 trial), addressing a large untapped market. This provides a clear competitive advantage and significant long-term growth potential. However, recent financial performance raises substantial concerns. The company reported declining gross margins (44% to 36%), consistent EPS misses, and a significant net loss, implying high cash burn. A major registered direct offering and warrants could lead to over 30% share dilution, significantly impacting shareholder value and making the path to 10x growth more challenging despite clinical advancements. While analyst sentiment is positive, the financial health and capital allocation aspects have materially weakened, tempering the overall high-risk, high-reward potential.

Unlock the full AI analysis for ICCM

Get the complete DVR score, risk analysis, and more

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

ICCM Price Targets & Strategy

12-Month Target

$1.40

Bull Case

$2.98

Bear Case

$0.20

Valuation Basis

Projected FY26 revenue of $6.8M (assuming ~100% YoY growth from FY25 $3.379M) x 20x P/S multiple / 97.2M diluted shares outstanding = $1.40/share.

Entry Strategy

Dollar-cost average between $0.30-$0.40, especially on dips, given the recent offering price of $0.50 as a potential reference point. Current price is already near recent lows post-dilution.

Exit Strategy

Take 50% profit at $1.50, reassess at $2.50. Place a stop loss if the price consistently trades below $0.25 (potential break of recent support zone).

Portfolio Allocation

5-7% for aggressive risk tolerance, considering the high-risk, high-reward profile and significant recent dilution.

Price Targets & Strategy

Upgrade to Premium for price targets and entry/exit strategies

Is ICCM Financially Healthy?

Valuation

P/E Ratio

-1.38

PEG Ratio

-0.67

Price/Book

20.51

Price/Sales

20.31

Profitability

Return on Equity

-230.80%

EPS

$-0.06

Balance Sheet

Current Ratio

1.18

Quick Ratio

0.72

Debt/Equity

0.82

Other

Beta (Volatility)

2.52

Does ICCM Have a Competitive Moat?

Moat Rating

🛡️ Narrow

Moat Trend

Expanding

Moat Sources

3 Identified

Intangible Assets/IP (proprietary ProSense technology, patents, clinical data)Switching Costs (for hospitals adopting the technology, training staff, integrating into workflows)Regulatory Advantages (FDA clearance, ASBrS guidelines)

The moat is strengthening due to continued clinical validation, regulatory approvals, and growing adoption which builds physician confidence and infrastructure. However, it's not 'Wide' due to potential for competing minimally invasive technologies or alternative cryoablation systems from larger players to emerge over a longer horizon.

Moat Erosion Risks

•Emergence of superior or cheaper competing non-surgical ablation technologies.
•Slow physician adoption or lack of reimbursement despite clinical evidence.
•Loss of key intellectual property protections or patent challenges.

ICCM Competitive Moat Analysis

ICCM Market Intelligence

Sentiment & Insider Activity

Social Sentiment

Mixed to Bearish. The significant recent price drop and dilution likely weigh heavily on retail investor sentiment, despite ongoing positive clinical news.

Institutional Sentiment

Positive. Analyst consensus remains 'Strong Buy' with a median price target of $2.98, indicating strong conviction in long-term potential despite recent financial struggles.

Insider Activity (Form 4)

VP BD & Global Marketing Tel-Tzure Tlalit Bussi reported initial ownership of 170,629 shares/RSUs on March 18, 2026 (Form 3), but no Form 4 buy/sell transactions were reported in the last 90 days.

Options Flow

Normal options activity; no unusual options activity indicating institutional positioning was reported.

Earnings Intelligence

Next Earnings

2026-06-03

Surprise Probability

Medium

Historical Earnings Pattern

Has consistently missed EPS estimates in recent quarters, suggesting potential for volatility or negative price reaction to further misses, despite some YoY EPS improvement in Q4 2025.

Key Metrics to Watch

Revenue growth rate (especially YoY from FY25 $3.379M)Gross margin trend (to confirm or reverse decline)Cash burn rate and runway after recent financing

Competitive Position

Top Competitor

Not specified in research data. However, other cryoablation or minimally invasive oncology device manufacturers would be key competitors.

Market Share Trend

Gaining. ProSense is noted to be 'gaining U.S. adoption' post-FDA clearance and ASBrS guidelines, with new hospital installations.

Valuation vs Peers

Trading at a significant premium on P/S (19.3x vs sector 2.9-3.2x) and P/B (9.2x vs sector 2.0-2.6x), despite declining gross margins and high cash burn, implying high expectations for future growth.

Competitive Advantages

•Proprietary cryoablation technology (ProSense) with unique clinical validation for breast cancer (ICE3 trial).
•Regulatory advantage with FDA clearance for low-risk breast cancer and ASBrS guideline inclusion.
•First-mover advantage in non-surgical breast cancer ablation in a largely untapped market.

Market Intelligence

Get sentiment, earnings intel, and peer analysis with Premium

What Could Drive ICCM Stock Higher?

Near-Term (0-6 months)

•Q1 2026 Earnings Report (expected June 3, 2026)
•Continued U.S. hospital installations and adoption of ProSense system
•Health Canada expansion approval for ProSense

Medium-Term (6-18 months)

•Enrollment acceleration for ChoICE study (H2 2026)
•Potential strategic partnerships for broader market penetration (e.g., international distribution)
•Expansion into new cryoablation indications beyond breast cancer

Long-Term (18+ months)

•ProSense becoming a standard of care for early-stage breast cancer ablation, disrupting traditional surgery
•Significant global market share capture in non-surgical tumor ablation
•Commercialization of new cryoablation technologies or applications

Catalysts & Growth Drivers

Upgrade to Premium to see catalysts

What's the Bull Case for ICCM?

✓
Acceleration in ProSense system installations and utilization rates reported quarterly.
✓
Reversal of the gross margin decline and clear improvement in profitability trajectory.
✓
Successful and timely completion/results from the ChoICE study.

Bull Case Analysis

See what could go right with Premium

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.

Analyze Any Stock →View Top 100 Deep Value Stocks →

How Icecure Medical Ltd Makes Money

Icecure Medical develops and commercializes the ProSense cryoablation system, a minimally invasive medical device that uses extreme cold to destroy tumors. The company makes money by selling these systems to hospitals and clinics, primarily for the treatment of small, low-risk breast cancer tumors as a non-surgical alternative. This approach aims to reduce patient recovery time and improve cosmetic outcomes compared to traditional surgery, positioning ProSense as a less invasive option for tumor removal.

Read Full Business Model Breakdown

FAQ

What is the DVR Score for Icecure Medical Ltd (ICCM)?

As of April 12, 2026, Icecure Medical Ltd has a DVR Score of 6.9 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

What is the market capitalization of Icecure Medical Ltd?

Icecure Medical Ltd's market capitalization is approximately $77.3M..

What is the risk level for ICCM stock?

Our analysis rates Icecure Medical Ltd's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.

What is the P/E ratio of ICCM?

Icecure Medical Ltd currently has a price-to-earnings (P/E) ratio of -1.4. This is below the market average, which could indicate the stock is undervalued or facing headwinds.

Is Icecure Medical Ltd's revenue growing?

Icecure Medical Ltd has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.

Is ICCM stock profitable?

Icecure Medical Ltd has a profit margin of 0.0%. The company is currently unprofitable.

How often is the ICCM DVR analysis updated?

Our AI-powered analysis of Icecure Medical Ltd is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 12, 2026.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ICCM (Icecure Medical Ltd) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.